Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 10:24 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 148 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Tamoxifen Clear all

Conditions: Breast Cancer, Hot Flashes, Menopausal Symptoms
Interventions: conjugated estrogens, medroxyprogesterone; Drug
Lead sponsor: Eastern Cooperative Oncology Group; Network
Eligibility: 18 Years to 120 Years · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2007
U.S. locations: 24
States / cities: Birmingham, Alabama • Chicago, Illinois • Decatur, Illinois + 16 more

Conditions: Breast Cancer
Interventions: octreotide acetate, tamoxifen citrate; Drug
Lead sponsor: NCIC Clinical Trials Group; Network
Eligibility: Up to 120 Years · Female only
Enrollment: 667 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1996 – 2010
U.S. locations: 2
States / cities: Duluth, Minnesota

Conditions: Breast Cancer Early Stage Breast Cancer (Stage 1-3)
Interventions: Fezolinetant, Placebo; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 92 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2028
U.S. locations: 2
States / cities: New Haven, Connecticut • Columbus, Ohio

Conditions: Metastatic Breast Cancer, Tumor, Muscle Neoplasms, Chronic Pain
Interventions: Method(s)1 Attribution, Method(s)2 Attribution,; Drug
Lead sponsor: DR. DIANE CHISESI NFS. MD. PHD.; Other
Eligibility: 44 Years to 59 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Colorado Springs, Colorado

Conditions: Estrogen Receptor Positive Breast Cancer
Interventions: TAK-228, Tamoxifen; Drug
Lead sponsor: The Methodist Hospital Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 3
States / cities: Houston, Texas • Sugar Land, Texas

Conditions: Endometrial Cancer
Interventions: filgrastim, cisplatin, doxorubicin hydrochloride, megestrol acetate, paclitaxel, tamoxifen citrate; Biological · Drug
Lead sponsor: Gynecologic Oncology Group; Network
Eligibility: Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2001
U.S. locations: 49
States / cities: Birmingham, Alabama • Los Angeles, California • Los Gatos, California + 41 more

Conditions: Brain and Central Nervous System Tumors
Interventions: tamoxifen citrate, radiation therapy; Drug · Radiation
Lead sponsor: Radiation Therapy Oncology Group; Network
Eligibility: 18 Years and older
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2000
U.S. locations: 237
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 184 more

Conditions: Brain and Central Nervous System Tumors
Interventions: carboplatin, tamoxifen citrate, temozolomide, adjuvant therapy, radiation therapy; Drug · Procedure · Radiation
Lead sponsor: San Diego Pacific Oncology & Hematology Associates; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 1
States / cities: Encinitas, California

Conditions: Menstruation Disturbances
Interventions: Tamoxifen, Placebo; Drug
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 15 Years to 45 Years · Female only
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Metastatic Breast Cancer
Interventions: Fulvestrant, Tamoxifen, Palbociclib; Drug
Lead sponsor: Shannon Puhalla; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Menorrhagia, Metrorrhagia, Medicated Intrauterine Devices
Interventions: Tamoxifen, Placebo (for Tamoxifen); Drug
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 15 Years to 45 Years · Female only
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Breast Cancer, Fertility
Interventions: Not listed
Lead sponsor: University of California, San Francisco; Other
Eligibility: 25 Years and older · Female only
Enrollment: 266 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Hodgkin's Disease, Breast Cancer
Interventions: Tamoxifen; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years to 35 Years · Female only
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2009
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Breast Cancer
Interventions: high performance liquid chromatography, laboratory biomarker analysis, mass spectrometry, medical chart review; Other
Lead sponsor: University of Nebraska; Other
Eligibility: 19 Years and older · Female only
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2012
U.S. locations: 2
States / cities: Rochester, Minnesota • Omaha, Nebraska

Conditions: Breast Cancer
Interventions: fulvestrant, tamoxifen citrate, conventional surgery, neoadjuvant therapy; Drug · Procedure
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: Female only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2004
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Breast Cancer, Hot Flashes, Hot Flushes
Interventions: soy protein, isoflavones, Tamoxifen, Placebo; Dietary Supplement · Drug · Other
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older · Female only
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2013
U.S. locations: 14
States / cities: Rockford, Illinois • Elkhart, Indiana • Kokomo, Indiana + 9 more

Conditions: Breast Neoplasms
Interventions: Exemestane, Celecoxib + Exemestane; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 111 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2008
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Breast Cancer
Interventions: tamoxifen citrate; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 35 Years to 120 Years · Female only
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2007
U.S. locations: 4
States / cities: Oklahoma City, Oklahoma • Dallas, Texas • Houston, Texas + 1 more

Conditions: Estrogen Receptor-negative Breast Cancer, HER2-negative Breast Cancer, Progesterone Receptor-negative Breast Cancer, Stage I Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Triple-negative Breast Cancer
Interventions: entinostat, anastrozole, diagnostic laboratory biomarker analysis, therapeutic conventional surgery; Drug · Other · Procedure
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years and older · Female only
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2017
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Breast Neoplasms
Interventions: exemestane (Aromasin), tamoxifen + exemestane; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 50 Years and older · Female only
Enrollment: 9,779 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2011
U.S. locations: 179
States / cities: Bessemer, Alabama • Birmingham, Alabama • Flagstaff, Arizona + 139 more

Conditions: Breast Cancer
Interventions: Tamoxifen Citrate, Placebo, Digital mammography, immunohistochemistry staining method, pharmacological study, laboratory biomarker analysis, protein expression analysis, pharmacogenomic studies, questionnaire administration, Fine needle aspiration, Quality of Life Assessment; Drug · Procedure · Other + 1 more
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 25 Years and older · Female only
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2028
U.S. locations: 12
States / cities: Birmingham, Alabama • Duarte, California • Aurora, Colorado + 9 more

Conditions: Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage 1 Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Estrogen Receptor-Positive Breast Carcinoma, HER2-Negative Breast Carcinoma, Breast Ductal Carcinoma In Situ, Breast Lobular Carcinoma In Situ
Interventions: Anastrozole, Letrozole, Exemestane, Tamoxifen, Mammogram, Magnetic Resonance Imaging, Dual X-ray Absorptiometry, Biospecimen Collection, Questionnaire Administration; Drug · Procedure · Biological + 1 more
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 1,556 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 728
States / cities: Anchorage, Alaska • Gilbert, Arizona • Goodyear, Arizona + 559 more

Conditions: Cognition, Aging
Interventions: tamoxifen, raloxifene; Drug
Lead sponsor: Wake Forest University; Other
Eligibility: 65 Years and older · Female only
Enrollment: 1,498 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2001 – 2008
U.S. locations: 127
States / cities: Phoenix, Arizona • Tucson, Arizona • Camp Pendleton, California + 102 more

Conditions: Breast Cancer, Early Breast Cancer
Interventions: Camizestrant, Tamoxifen, Anastrozole, Letrozole, Exemestane, Abemaciclib; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 5,511 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2037
U.S. locations: 111
States / cities: Dothan, Alabama • Phoenix, Arizona • Tucson, Arizona + 98 more

Search by objective public record fields.

Hormone Replacement Therapy for Hot Flashes and/or Vaginal Symptoms in Postmenopausal Women Receiving Tamoxifen for Breast Cancer

Tamoxifen With or Without Octreotide in Treating Postmenopausal Women With Stage I, Stage II, or Stage III Breast Cancer

FLASH-Breast: Evaluating the Efficacy of Fezolinetant in Reducing Vasomotor Symptoms in Women With Breast Cancer on Endocrine Therapy

Anastrozole Adjuvant Trial - Study of Anastrozole Compared to NOLVADEX (Tamoxifen Citrate) for Adjuvant Treatment of Early Breast Cancer Clinical Studies), Adjunct Cytotoxic Chemotherapy and Malignant Joint Tumor

TAK-228 Plus Tamoxifen in Patients With ER-Positive, HER2-negative Breast Cancer

Combination Chemotherapy Compared With Hormone Therapy in Treating Patients With Recurrent, Stage III, or Stage IV Endometrial Cancer

Radiation Therapy and Tamoxifen in Treating Adults With Newly Diagnosed Supratentorial Glioblastoma Multiforme

Radiation Therapy, Temozolomide, Tamoxifen, and Carboplatin in Treating Patients With Malignant Gliomas

Tamoxifen for the Treatment of Unfavorable Bleeding in Contraceptive Implant Users

Treatment of Metastatic Breast Cancer With Fulvestrant Plus Palbociclib or Tamoxifen Plus Palbociclib

Tamoxifen to Reduce Unscheduled Bleeding in New Users of the Levonorgestrel-releasing Intrauterine System (LNG-IUS)

Investigating the Impact of Tamoxifen Therapy on Ovarian Aging

Tamoxifen in the Prevention of Breast Cancer in Hodgkin's Disease Survivors

Effect of Tamoxifen or an Aromatase Inhibitor on Estrogen Metabolism in Women Treated for Newly Diagnosed Breast Cancer

Fulvestrant or Tamoxifen in Treating Postmenopausal Women Who Are Undergoing Surgery for Ductal Carcinoma in Situ of the Breast

Soy Protein Supplement In Treating Hot Flashes in Postmenopausal Women Receiving Tamoxifen for Breast Disease

Open-Label Study Of Exemestane With Or Without Celecoxib In Postmenopausal Women With ABC Having Progressed On Tamoxifen

Tamoxifen in Preventing Breast Cancer in Women at Increased Risk for Breast Cancer

Entinostat and Anastrozole in Treating Postmenopausal Women With TNBC That Can Be Removed by Surgery

Randomized Phase III Study Of Exemestane (Aromasin) For 5 Years Versus Tamoxifen for 2.5 to 3 Years Followed By Exemestane

Low-Dose Tamoxifen Citrate in Reducing Breast Cancer Risk in Radiation-Induced Cancer Survivors

Testing Low Dose Tamoxifen for Invasive Breast Cancer, LoTam Trial

Cognition in the Study of Tamoxifen and Raloxifene

An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)